Literature DB >> 21207213

Flow cytometric analysis of de novo acute myeloid leukemia in childhood: report from the Japanese Pediatric Leukemia/Lymphoma Study Group.

Hideaki Ohta, Shotaro Iwamoto, Nobutaka Kiyokawa, Masahito Tsurusawa, Takao Deguchi, Kozo Takase, Junichiro Fujimoto, Keizo Horibe, Yoshihiro Komada.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21207213     DOI： 10.1007/s12185-010-0754-y

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  10 in total

1.  Expression of CD7 on normal human myeloid progenitors.

Authors:  C Chabannon; P Wood; B Torok-Storb
Journal:  J Immunol       Date:  1992-09-15       Impact factor: 5.422

2.  Flow cytometric immunophenotypic characterization of pediatric and adult minimally differentiated acute myeloid leukemia (AML-M0).

Authors:  P K Kotylo; I S Seo; F O Smith; N A Heerema; N S Fineberg; K Miller; M E Greene; P Chou; A Orazi
Journal:  Am J Clin Pathol       Date:  2000-02       Impact factor: 2.493

3.  Immunophenotyping of leukemia.

Authors:  D Campana; F G Behm
Journal:  J Immunol Methods       Date:  2000-09-21       Impact factor: 2.303

Review 4.  Diagnosis of childhood acute myeloid leukemia.

Authors:  F G Behm
Journal:  Clin Lab Med       Date:  1999-03       Impact factor: 1.935

Review 5.  Acute myeloid leukaemia M0: haematological, immunophenotypic and cytogenetic characteristics and their prognostic significance: an analysis in 241 patients.

Authors:  M C Béné; M Bernier; R O Casasnovas; G Castoldi; D Doekharan; B van der Holt; W Knapp; P Lemez; W D Ludwig; E Matutes; A Orfao; C Schoch; C Sperling; M B van't Veer
Journal:  Br J Haematol       Date:  2001-06       Impact factor: 6.998

6.  Phenotypical characteristics of acute myelocytic leukemia associated with the t(8;21)(q22;q22) chromosomal abnormality: frequent expression of immature B-cell antigen CD19 together with stem cell antigen CD34.

Authors:  K Kita; K Nakase; H Miwa; M Masuya; K Nishii; N Morita; N Takakura; A Otsuji; S Shirakawa; T Ueda
Journal:  Blood       Date:  1992-07-15       Impact factor: 22.113

Review 7.  Progress in understanding and managing natural killer-cell malignancies.

Authors:  Kazuo Oshimi
Journal:  Br J Haematol       Date:  2007-10-03       Impact factor: 6.998

8.  Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87.

Authors:  U Creutzig; J Harbott; C Sperling; J Ritter; M Zimmermann; H Löffler; H Riehm; G Schellong; W D Ludwig
Journal:  Blood       Date:  1995-10-15       Impact factor: 22.113

9.  Distinctive immunophenotypic features of t(8;21)(q22;q22) acute myeloblastic leukemia in children.

Authors:  C A Hurwitz; S C Raimondi; D Head; R Krance; J Mirro; D K Kalwinsky; G D Ayers; F G Behm
Journal:  Blood       Date:  1992-12-15       Impact factor: 22.113

10.  Flow cytometric analysis of acute leukemias. Diagnostic utility and critical analysis of data.

Authors:  Zahid Kaleem; Eric Crawford; M Hanif Pathan; Leah Jasper; Michael A Covinsky; Lawrence R Johnson; Glenda White
Journal:  Arch Pathol Lab Med       Date:  2003-01       Impact factor: 5.534
  10 in total
  2 in total

Review 1.  Global characteristics of childhood acute promyelocytic leukemia.

Authors:  L Zhang; A Samad; M S Pombo-de-Oliveira; G Scelo; M T Smith; J Feusner; J L Wiemels; C Metayer
Journal:  Blood Rev       Date:  2014-09-30       Impact factor: 8.250

2.  Appropriate dose reduction in induction therapy is essential for the treatment of infants with acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group.

Authors:  Daisuke Tomizawa; Akio Tawa; Tomoyuki Watanabe; Akiko Moriya Saito; Kazuko Kudo; Takashi Taga; Shotaro Iwamoto; Akira Shimada; Kiminori Terui; Hiroshi Moritake; Akitoshi Kinoshita; Hiroyuki Takahashi; Hideki Nakayama; Nobutaka Kiyokawa; Keiichi Isoyama; Shuki Mizutani; Junichi Hara; Keizo Horibe; Tatsutoshi Nakahata; Souichi Adachi
Journal:  Int J Hematol       Date:  2013-09-26       Impact factor: 2.490
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.